Occurrence and Management of Immunotherapy-Associated Adverse Events in Patients with Gynecological Cancers.

Simple Summary: The implementation of immune checkpoint inhibitors into the therapeutic armamentarium for many solid tumors has transformed the treatment landscape of gynecological malignancies. The mechanism of action of immune checkpoint inhibitors is to increase the body's own tumor-directed T-cell response, which can, however, lead to a new spectrum of immunotherapy-associated adverse events (irAEs). In the present study, we retrospectively analyzed the incidence, diagnosis, and management of irAEs in patients with gynecologic malignancies who received immune checkpoint inhibitors and discussed our findings in the context of the recent literature. Our results emphasize the need for proactive monitoring and tailored management strategies to optimize the safety and efficacy of immunotherapy in cancer patients. Background: Immune checkpoint inhibitors (ICIs) have emerged as an essential therapeutic approach in treating many solid tumors. ICIs enhance the body's anti-tumor T-cell activity, resulting in a novel spectrum of immunotherapy-related side effects. This novel spectrum of adverse events differs significantly from the side effects of conventional chemotherapy. It, therefore, requires special attention in the diagnosis and management of immunotherapy-related adverse events (irAEs). The present study aimed to retrospectively analyze the incidence, diagnosis, and management of irAEs in patients with gynecologic malignancies who received ICIs and to discuss these findings in the context of the recent literature. Methods: In the present retrospective overview, we evaluated patients with gynecologic malignancies (breast, endometrial, cervical, ovarian) who received ICIs with regard to the incidence, type, and time to onset of irAEs. A total of 61 patients treated at the Department of Gynecology and Obstetrics, University Medical Center Mainz, Germany, between 2018 and 2023 were included in the analysis. Results: A total of 32.8% of patients developed an irAE of any grade or type. The median time to irAE was 24 weeks. The most frequently observed irAEs were grade 1 (20%) or 2 (35%). Immunotherapy-related grade 3 or 4 adverse events occurred in 45% of patients (40% grade 3, 5% grade 4). The most common type of irAE in our cohort was hypothyroidism, followed by hepatitis and colitis. Cox regression analysis identified the duration of ICI therapy as the only significant factor influencing the incidence of irAEs (p = 0.004). Conclusion: The broad spectrum of irAEs and the onset time of irAEs are important challenges of therapy with ICIs, requiring proactive monitoring and tailored management strategies to optimize the safety and efficacy of immunotherapy. [ABSTRACT FROM AUTHOR]